[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100579553":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":26,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":25,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":25,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":25,"overallStatus":58,"whyStopped":25,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":25},{"fullName":5,"class":6},"Beijing Chao Yang Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"SLR group","SHAM_COMPARATOR","Patients with a weight loss of less than 5% at the end of treatment are defined as semaglutide low responders (SLR).",[13],"Drug: Semaglutide Subcutaneous Injection",{"label":15,"type":16,"description":17,"interventionNames":18},"SHR group","ACTIVE_COMPARATOR","Patients who experience a weight reduction of ≥15% at the treatment endpoint are defined as high responders to semaglutide (SHR).",[13],[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Semaglutide Subcutaneous Injection","All subjects received subcutaneous injections of semaglutide over a 28-week treatment period, which included an initial 16-week dose-escalation phase. The escalation protocol began with a starting dose of 0.25 mg administered once weekly. Every 4 weeks, the dose was gradually increased in a stepwise manner to 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg, each administered once weekly.",[15,9],null,[27],{"name":28,"affiliation":5,"role":29},"Guang Wang","STUDY_CHAIR",[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Jia Liu","CONTACT","010-85231710","liujia0116@126.com",{"type":37,"investigatorFullName":32,"investigatorTitle":38,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"PRINCIPAL_INVESTIGATOR","Director of Endocrinology","100579553","semaglutides-weight-loss-effects-in-obesity-100579553",false,"NCT06825793","Semaglutide's Weight Loss Effects in Obesity","Clinical Assessment of Semaglutide-Induced Weight Reduction in Obese Populations","Inclusion Criteria:\n\n* Age 18-60 years\n* BMI ≥ 30 kg\u002Fm²\n* At least one self-reported unsuccessful attempt at lifestyle weight loss\n\nExclusion Criteria:\n\n* Weight change (self-reported) \\> 5% in the past 3 months prior to screening\n* Use of any medication for obesity indication in the past 3 months prior to screening.\n* Use of antidiabetic medications in the past 3 months, or HbA1c ≥ 6.5%, or a history of Type 1 or Type 2 diabetes.\n* Use of immunosuppressants, corticosteroids, antidiarrheal drugs, antibiotics, probiotics, lipid-lowering medications, and\u002For other gastrointestinal motility drugs in the past 3 months prior to screening.\n* A history of endocrine-related overweight or obesity diagnoses, such as Cushing's syndrome.\n* Triglycerides ≥ 500 mg\u002FdL (5.65 mmol\u002FL) at screening.\n* Known clinically significant gastric emptying abnormalities (e.g., severe diabetic gastroparesis or gastric outlet obstruction), gastrointestinal diseases, or surgical history.\n* Thyroid dysfunction.\n* History of mental illness.\n* History or family history of multiple endocrine neoplasia or medullary thyroid cancer, or calcitonin ≥ 6 pg\u002FmL.\n* Abnormal liver function at screening, defined as alanine aminotransferase (ALT) and\u002For aspartate aminotransferase (AST) \\> 3\\*ULN.\n* Abnormal kidney function at screening, defined as estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.75m².\n* History of cardiovascular disease.\n* History of malignancy.\n* Pregnancy or breastfeeding.\n* Any other physiological, psychological, or other conditions deemed by the investigator as unsuitable for participation in the trial.","ALL","18 Years","60 Years",{"count":50,"type":51},56,"ESTIMATED","INTERVENTIONAL",[54],"NA","This is a non-randomized, concurrent, parallel-controlled clinical trial. The objective of this trial is to determine the relationship between weight loss responsiveness to semaglutide in obese patients and their gut microbiota.",[57],"Obesity","NOT_YET_RECRUITING","2025-02-08",{"date":61,"type":62},"2025-02-13","ACTUAL",{"date":64,"type":51},"2025-02-20",{"date":66,"type":51},"2027-12-31",{"name":5,"class":6}]